GlassScriptPhysician profile
Tejaswi Sastry
NPI 1013005685
$5,093.44
in general payments reported to CMS, 2019-2025
40 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $151 · 2021: $210 · 2022: $313 · 2023: $702 · 2024: $1,961 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,745 · Long Term Medical Supply Or Device Loan: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.17 |
| Long Term Medical Supply Or Device Loan | $997.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,754.29 | 2019-2025 | |
| Pfizer INC. | $463.42 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $323.75 | 2019-2025 | Eliquis, Camzyos |
| Myriad Genetic Laboratories, INC. | $219.68 | 2023-2024 | Precisetumor |
| Daiichi Sankyo INC. | $187.18 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $186.13 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Pharmaessentia USA Corporation | $183.79 | 2023-2025 | Besremi |
| Incyte Corporation | $141.22 | 2019-2024 | Jakafi |
| Glaxosmithkline, LLC. | $136.41 | 2024-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $126.44 | 2019-2025 | Enhertu, Calquence |
| Genentech USA, INC. | $104.07 | 2019-2025 | Alecensa, Tecentriq, Tecentriq Hybreza |
| Abbvie INC. | $94.74 | 2020-2025 | Venclexta |
| Janssen Pharmaceuticals, INC | $88.07 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $83.42 | 2019-2025 | Keytruda, Welireg |
| Amgen INC. | $82.88 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejaswi Sastry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.